Desmopressin in moderate hemophilia a patients: A treatment worth considering

Rise Consortium

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response, therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter Response to DDAVP In non-severe hemophilia A patients: in Search for dEterminants (RISE) cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30, and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and von Willebrand factor antigen, peak von Willebrand factor activity and desmopressin-induced rise in von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65% of the inter-individual variation. In 40% of moderate hemophilia A patients, desmopressin response was adequate, thus it is important not to withhold this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin-induced factor VIII rise, factor VIII activity and desmopressin-induced rise in von Willebrand factor antigen had the strongest effect.

Original languageEnglish
Pages (from-to)550-557
Number of pages8
JournalHaematologica
Volume103
Issue number3
DOIs
Publication statusPublished - Feb 28 2018

Fingerprint

Deamino Arginine Vasopressin
Hemophilia A
Factor VIII
Therapeutics
von Willebrand Factor
Intravenous Administration
Linear Models

ASJC Scopus subject areas

  • Hematology

Cite this

Desmopressin in moderate hemophilia a patients : A treatment worth considering. / Rise Consortium.

In: Haematologica, Vol. 103, No. 3, 28.02.2018, p. 550-557.

Research output: Contribution to journalArticle

Rise Consortium. / Desmopressin in moderate hemophilia a patients : A treatment worth considering. In: Haematologica. 2018 ; Vol. 103, No. 3. pp. 550-557.
@article{6947ddfcd7ab459d841850459658e0ac,
title = "Desmopressin in moderate hemophilia a patients: A treatment worth considering",
abstract = "Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response, therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter Response to DDAVP In non-severe hemophilia A patients: in Search for dEterminants (RISE) cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30, and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40{\%}), of whom 25 showed excellent response (15{\%}). Intravenous administration, age, pre-desmopressin factor VIII activity and von Willebrand factor antigen, peak von Willebrand factor activity and desmopressin-induced rise in von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65{\%} of the inter-individual variation. In 40{\%} of moderate hemophilia A patients, desmopressin response was adequate, thus it is important not to withhold this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin-induced factor VIII rise, factor VIII activity and desmopressin-induced rise in von Willebrand factor antigen had the strongest effect.",
author = "{Rise Consortium} and Loomans, {Janneke I.} and Kruip, {Marieke J.H.A.} and Manuel Carcao and Shannon Jackson and {van Velzen}, {Alice S.} and Marjolein Peters and Elena Santagostino and Helen Platokouki and Erik Beckers and Jan Voorberg and {van der Bom}, {Johanna G.} and Karin Fijnvandraat",
year = "2018",
month = "2",
day = "28",
doi = "10.3324/haematol.2017.180059",
language = "English",
volume = "103",
pages = "550--557",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Desmopressin in moderate hemophilia a patients

T2 - A treatment worth considering

AU - Rise Consortium

AU - Loomans, Janneke I.

AU - Kruip, Marieke J.H.A.

AU - Carcao, Manuel

AU - Jackson, Shannon

AU - van Velzen, Alice S.

AU - Peters, Marjolein

AU - Santagostino, Elena

AU - Platokouki, Helen

AU - Beckers, Erik

AU - Voorberg, Jan

AU - van der Bom, Johanna G.

AU - Fijnvandraat, Karin

PY - 2018/2/28

Y1 - 2018/2/28

N2 - Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response, therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter Response to DDAVP In non-severe hemophilia A patients: in Search for dEterminants (RISE) cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30, and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and von Willebrand factor antigen, peak von Willebrand factor activity and desmopressin-induced rise in von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65% of the inter-individual variation. In 40% of moderate hemophilia A patients, desmopressin response was adequate, thus it is important not to withhold this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin-induced factor VIII rise, factor VIII activity and desmopressin-induced rise in von Willebrand factor antigen had the strongest effect.

AB - Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response, therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter Response to DDAVP In non-severe hemophilia A patients: in Search for dEterminants (RISE) cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30, and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and von Willebrand factor antigen, peak von Willebrand factor activity and desmopressin-induced rise in von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65% of the inter-individual variation. In 40% of moderate hemophilia A patients, desmopressin response was adequate, thus it is important not to withhold this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin-induced factor VIII rise, factor VIII activity and desmopressin-induced rise in von Willebrand factor antigen had the strongest effect.

UR - http://www.scopus.com/inward/record.url?scp=85042748259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042748259&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.180059

DO - 10.3324/haematol.2017.180059

M3 - Article

AN - SCOPUS:85042748259

VL - 103

SP - 550

EP - 557

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -